Rock Springs Capital Management LP Blueprint Medicines Corp Transaction History

Rock Springs Capital Management LP

$3.22 Billion
Q2 2024

A detailed history of Rock Springs Capital Management LP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Rock Springs Capital Management LP holds 2,460,417 shares of BPMC stock, worth $227 Million. This represents 8.22% of its overall portfolio holdings.

Number of Shares

2,460,417

Previous 2,498,448 1.52%

Holding current value

$227 Million

Previous $237 Million 11.89%

% of portfolio

8.22%

Previous 6.2%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$85.18 - $108.78 $3.24 Million - $4.14 Million	-38,031 Reduced 1.52%	2,460,417 $265 Million
Q1 2024 May 15, 2024	SELL	$73.17 - $99.79 $28 Million - $38.2 Million	-383,119 Reduced 13.3%	2,498,448 $237 Million
Q4 2023 Feb 14, 2024	BUY	$43.96 - $92.84 $8.63 Million - $18.2 Million	196,273 Added 7.31%	2,881,567 $266 Million
Q3 2023 Nov 14, 2023	BUY	$46.9 - $66.0 $23.4 Million - $32.9 Million	498,622 Added 22.8%	2,685,294 $135 Million
Q2 2023 Aug 14, 2023	BUY	$42.2 - $66.37 $6.48 Million - $10.2 Million	153,624 Added 7.56%	2,186,672 $138 Million
Q1 2023 May 15, 2023	BUY	$37.97 - $50.0 $5.37 Million - $7.08 Million	141,538 Added 7.48%	2,033,048 $91.5 Million
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $14.5 Million - $23.5 Million	353,315 Added 22.97%	1,891,510 $82.9 Million
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $27.9 Million - $43.4 Million	559,021 Added 57.09%	1,538,195 $101 Million
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $1.42 Million - $2.21 Million	31,459 Added 3.32%	979,174 $49.5 Million
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $4.76 Million - $9.68 Million	87,960 Added 10.23%	947,715 $60.5 Million
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $951,548 - $1.17 Million	10,096 Added 1.19%	859,755 $92.1 Million
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $3.3 Million - $4.47 Million	40,799 Added 5.04%	849,659 $87.4 Million
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $5.14 Million - $6.27 Million	62,128 Added 8.32%	808,860 $71.1 Million
Q1 2021 May 17, 2021	SELL	$90.71 - $108.28 $8.64 Million - $10.3 Million	-95,268 Reduced 11.31%	746,732 $72.6 Million
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $10.2 Million - $13.8 Million	-110,773 Reduced 11.63%	842,000 $94.4 Million
Q3 2020 Nov 16, 2020	SELL	$66.45 - $92.7 $482,161 - $672,631	-7,256 Reduced 0.76%	952,773 $88.3 Million
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $12.7 Million - $17.7 Million	223,029 Added 30.26%	960,029 $74.9 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $17.1 Million - $29.2 Million	355,000 Added 92.93%	737,000 $43.1 Million
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $3.24 Million - $4.01 Million	48,500 Added 14.54%	382,000 $30.6 Million
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $1.9 Million - $2.64 Million	26,000 Added 8.46%	333,500 $24.5 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $2.39 Million - $3.18 Million	32,500 Added 11.82%	307,500 $29 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $2.99 Million - $5.31 Million	61,342 Added 28.71%	275,000 $22 Million
Q4 2018 Feb 14, 2019	BUY	$45.57 - $74.26 $622,395 - $1.01 Million	13,658 Added 6.83%	213,658 $11.5 Million
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $58,910 - $78,320	1,000 Added 0.5%	200,000 $15.6 Million
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $2.51 Million - $4.17 Million	41,247 Added 26.15%	199,000 $12.6 Million
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $824,619 - $1.16 Million	11,253 Added 7.68%	157,753 $14.5 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $3.77 Million - $5.3 Million	60,000 Added 69.36%	146,500 $11 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $3.67 Million - $6.03 Million	86,500	86,500 $6.03 Million

Others Institutions Holding BPMC

# of Institutions

340

Shares Held

62M

Call Options Held

987K

Put Options Held

578K

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.52B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.

Account

Rock Springs Capital Management LP Blueprint Medicines Corp Transaction History